Podcasts about gilotrif

Play Episode Listen Later Feb 19, 2016 2:54

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

positive therapy cancer trial stage match iv expression targeted lung mutation cleveland clinic chemotherapy her2 nsclc pennell herceptin gracecast cancergrace nathan pennell afatinib gcvl gcvllung gilotrif

HER2 Mutation Positive NSCLC

Play Episode Listen Later Feb 19, 2016 2:54

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

positive therapy cancer trial stage match iv expression targeted lung mutation cleveland clinic chemotherapy her2 nsclc pennell herceptin gracecast cancergrace nathan pennell afatinib gcvl gcvllung gilotrif

HER2 Mutation Positive NSCLC

Play Episode Listen Later Feb 19, 2016 2:54

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

positive therapy cancer trial stage match iv expression targeted lung mutation cleveland clinic chemotherapy her2 nsclc pennell herceptin gracecast cancergrace nathan pennell afatinib gcvl gcvllung gilotrif

Third Generation EGFR TKIs for Acquired Resistance

Play Episode Listen Later Feb 17, 2016 3:07

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib

Third Generation EGFR TKIs for Acquired Resistance

Play Episode Listen Later Feb 17, 2016 3:07

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib

Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

Play Episode Listen Later Feb 17, 2016 4:26

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

body positive therapy cancer generation stage options iv targeted lung mutation cleveland clinic chemotherapy combinations inhibitors egfr radiotherapy ablation alk nsclc pennell sbrt stereotactic cetuximab gracecast cancergrace crizotinib acquired resistance nathan pennell tarceva erbitux afatinib xalkori gilotrif

Third Generation EGFR TKIs for Acquired Resistance

Play Episode Listen Later Feb 17, 2016 3:07

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib

Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

Play Episode Listen Later Feb 17, 2016 4:26

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

body positive therapy cancer generation stage options iv targeted lung mutation cleveland clinic chemotherapy combinations inhibitors egfr radiotherapy ablation alk nsclc pennell sbrt stereotactic cetuximab gracecast cancergrace crizotinib acquired resistance nathan pennell tarceva erbitux afatinib xalkori gilotrif

Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

Play Episode Listen Later Feb 17, 2016 4:26

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

body positive therapy cancer generation stage options iv targeted lung mutation cleveland clinic chemotherapy combinations inhibitors egfr radiotherapy ablation alk nsclc pennell sbrt stereotactic cetuximab gracecast cancergrace crizotinib acquired resistance nathan pennell tarceva erbitux afatinib xalkori gilotrif

Targeted Therapies in a Post-Operative/Adjuvant Setting

Play Episode Listen Later Feb 11, 2016 3:48

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

therapy cancer trial stage disease alchemists targeted lung mutation radiant ib cleveland clinic operative egfr alk nsclc targeted therapy adjuvant pennell gracecast cancergrace crizotinib nathan pennell tarceva xalkori gilotrif gcvl gcvllung micrometastatic

Targeted Therapies in a Post-Operative/Adjuvant Setting

Play Episode Listen Later Feb 11, 2016 3:48

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

therapy cancer trial stage disease alchemists targeted lung mutation radiant ib cleveland clinic operative egfr alk nsclc targeted therapy adjuvant pennell gracecast cancergrace crizotinib nathan pennell tarceva xalkori gilotrif gcvl gcvllung micrometastatic

Targeted Therapies in a Post-Operative/Adjuvant Setting

Play Episode Listen Later Feb 11, 2016 3:48

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

therapy cancer trial stage disease alchemists targeted lung mutation radiant ib cleveland clinic operative egfr alk nsclc targeted therapy adjuvant pennell gracecast cancergrace crizotinib nathan pennell tarceva xalkori gilotrif gcvl gcvllung micrometastatic

Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West

Play Episode Listen Later Jan 10, 2016 26:34

Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

west cancer institute patients treatments resistance swedish forum memorial drs lung mutation acquired sequencing egfr nsclc panel q sloan kettering jack west mskcc cetuximab riely gracecast t790m cancergrace nonsmall erbitux afatinib greg riely gilotrif azd9291 co1686

Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West

Play Episode Listen Later Jan 10, 2016 26:34

Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

west cancer institute patients treatments resistance swedish forum memorial drs lung mutation acquired sequencing egfr nsclc panel q sloan kettering jack west mskcc cetuximab riely gracecast t790m cancergrace nonsmall erbitux afatinib greg riely gilotrif azd9291 co1686

Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West

Play Episode Listen Later Jan 10, 2016 26:34

Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

west cancer institute patients treatments resistance swedish forum memorial drs lung mutation acquired sequencing egfr nsclc panel q sloan kettering jack west mskcc cetuximab riely gracecast t790m cancergrace nonsmall erbitux afatinib greg riely gilotrif azd9291 co1686

Treatment Options for EGFR T790M Negative Acquired Resistance

Play Episode Listen Later Jan 9, 2016 24:36

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

west cancer institute patients resistance negative swedish forum lung mutation acquired treatment options egfr nsclc jack west osimertinib cetuximab gracecast t790m cancergrace acquired resistance nonsmall erbitux afatinib azd9291 gilotrif th4000 co1686 rociletinib

Treatment Options for EGFR T790M Negative Acquired Resistance

Play Episode Listen Later Jan 9, 2016 24:36

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

west cancer institute patients resistance negative swedish forum lung mutation acquired treatment options egfr nsclc jack west osimertinib cetuximab gracecast t790m cancergrace acquired resistance nonsmall erbitux afatinib azd9291 gilotrif th4000 co1686 rociletinib

Treatment Options for EGFR T790M Negative Acquired Resistance

Play Episode Listen Later Jan 9, 2016 24:36

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

west cancer institute patients resistance negative swedish forum lung mutation acquired treatment options egfr nsclc jack west osimertinib cetuximab gracecast t790m cancergrace acquired resistance nonsmall erbitux afatinib azd9291 gilotrif th4000 co1686 rociletinib

Emerging Options for T790M-Positive Acquired Resistance

Play Episode Listen Later Jan 8, 2016 13:53

positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib

Emerging Options for T790M-Positive Acquired Resistance

Play Episode Listen Later Jan 8, 2016 13:53

positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib

Emerging Options for T790M-Positive Acquired Resistance

Play Episode Listen Later Jan 8, 2016 13:53

positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib

Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?

Play Episode Listen Later Dec 9, 2015 3:15

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

west rare horn drs oral mutation substitution inhibitor deletion egfr exon jack west gracecast l858r wclc cancergrace erlotinib leora horn tarceva iressa afatinib gefitinib gilotrif

Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?

Play Episode Listen Later Dec 9, 2015 3:15

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

west rare horn drs oral mutation substitution inhibitor deletion egfr exon jack west gracecast l858r wclc cancergrace erlotinib leora horn tarceva iressa afatinib gefitinib gilotrif

Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?

Play Episode Listen Later Dec 9, 2015 3:15

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

west rare horn drs oral mutation substitution inhibitor deletion egfr exon jack west gracecast l858r wclc cancergrace erlotinib leora horn tarceva iressa afatinib gefitinib gilotrif

Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

Play Episode Listen Later Dec 8, 2015 3:25

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

west treatments resistance differences significant horn drs sequence mutation acquired clinically second generation egfr tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn tarceva iressa azd9291 gilotrif co1686 rociletinib merelitinib

Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

Play Episode Listen Later Dec 8, 2015 3:25

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

west treatments resistance differences significant horn drs sequence mutation acquired clinically second generation egfr tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn tarceva iressa azd9291 gilotrif co1686 rociletinib merelitinib

Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

Play Episode Listen Later Dec 8, 2015 3:25

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

west treatments resistance differences significant horn drs sequence mutation acquired clinically second generation egfr tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn tarceva iressa azd9291 gilotrif co1686 rociletinib merelitinib

Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?

Play Episode Listen Later Oct 6, 2015 7:48

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

growth positive therapy factor added mutation substitution receptor deletion egfr nsclc exon tki avastin bevacizumab jack west epidermal gracecast l858r egfr tki cancergrace erlotinib tarceva iressa antiangiogenesis afatinib gefitinib gcvl gcvllung gilotrif

Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?

Play Episode Listen Later Oct 6, 2015 7:48

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

growth positive therapy factor added mutation substitution receptor deletion egfr nsclc exon tki avastin bevacizumab jack west epidermal gracecast l858r egfr tki cancergrace erlotinib tarceva iressa antiangiogenesis afatinib gefitinib gcvl gcvllung gilotrif

Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?

Play Episode Listen Later Oct 6, 2015 7:48

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

growth positive therapy factor added mutation substitution receptor deletion egfr nsclc exon tki avastin bevacizumab jack west epidermal gracecast l858r egfr tki cancergrace erlotinib tarceva iressa antiangiogenesis afatinib gefitinib gcvl gcvllung gilotrif

Debating EGFR Inhibitors for Squamous Cell Lung Cancer Patients

Play Episode Listen Later Jul 2, 2015 7:22

Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.

west data cancer institute swedish gandhi debating institut lung cancer patients lung cancer soria asco inhibitors jean charles gustave egfr carcinoma dana farber squamous gracecast cancergrace roussy erlotinib tarceva afatinib gilotrif

Debating EGFR Inhibitors for Squamous Cell Lung Cancer Patients

Play Episode Listen Later Jul 2, 2015 7:22

Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.

west data cancer institute swedish gandhi debating institut lung cancer patients lung cancer soria asco inhibitors jean charles gustave egfr carcinoma dana farber squamous gracecast cancergrace roussy erlotinib tarceva afatinib gilotrif

Debating EGFR Inhibitors for Squamous Cell Lung Cancer Patients

Play Episode Listen Later Jul 2, 2015 7:22

Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.

west data cancer institute swedish gandhi debating institut lung cancer patients lung cancer soria asco inhibitors jean charles gustave egfr carcinoma dana farber squamous gracecast cancergrace roussy erlotinib tarceva afatinib gilotrif

Novel EGFR Inhibitors in the Setting of Acquired Resistance

Play Episode Listen Later Nov 11, 2014 26:27

Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790

Novel EGFR Inhibitors in the Setting of Acquired Resistance

Play Episode Listen Later Nov 11, 2014 26:27

Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790

Novel EGFR Inhibitors in the Setting of Acquired Resistance

Play Episode Listen Later Nov 11, 2014 26:27

Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.

cancer institute pasi inhibitors dana farber cancer institute egfr dana farber gracecast t790m cancergrace acquired resistance erlotinib tarceva iressa afatinib dacomitinib gefitinib azd9291 gilotrif co1686 acquired resistance forum video ap26113 t790

Will HER2 Inhibitor Drugs Help Lung Cancer Patients?

Play Episode Listen Later Sep 7, 2014 4:05

HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.

therapy cancer institute drugs gandhi targeted lung cancer patients lung cancer her2 inhibitor dana farber paclitaxel gracecast cancergrace abraxane afatinib gilotrif

Will HER2 Inhibitor Drugs Help Lung Cancer Patients?

Play Episode Listen Later Sep 7, 2014 4:05

HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.

therapy cancer institute drugs gandhi targeted lung cancer patients lung cancer her2 inhibitor dana farber paclitaxel gracecast cancergrace abraxane afatinib gilotrif

Will HER2 Inhibitor Drugs Help Lung Cancer Patients?

Play Episode Listen Later Sep 7, 2014 4:05

HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.

therapy cancer institute drugs gandhi targeted lung cancer patients lung cancer her2 inhibitor dana farber paclitaxel gracecast cancergrace abraxane afatinib gilotrif

Does Gilotrif Help EGFR Positive Lung Cancer Patients?

Play Episode Listen Later Jun 18, 2014 8:16

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

university school west medicine positive cancer institute indiana swedish yang northwestern lung lux cancer patients lung cancer nasser asco egfr cisplatin gemcitabine gracecast cancergrace alimta gemzar pemetrexed afatinib gilotrif

Does Gilotrif Help EGFR Positive Lung Cancer Patients?

Play Episode Listen Later Jun 18, 2014 8:16

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

university school west medicine positive cancer institute indiana swedish yang northwestern lung lux cancer patients lung cancer nasser asco egfr cisplatin gemcitabine gracecast cancergrace alimta gemzar pemetrexed afatinib gilotrif

Does Gilotrif Help EGFR Positive Lung Cancer Patients?

Play Episode Listen Later Jun 18, 2014 8:16

An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

university school west medicine positive cancer institute indiana swedish yang northwestern lung lux cancer patients lung cancer nasser asco egfr cisplatin gemcitabine gracecast cancergrace alimta gemzar pemetrexed afatinib gilotrif

How Do We Make EGFR Inhibitors Work Better for Patients

Play Episode Listen Later Jun 9, 2014 3:15

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.

cancer institute patients treatments geoffrey lung combination oxnard inhibitors work better dana farber cancer institute egfr dana farber gracecast cancergrace tarceva iressa afatinib gefitinib gilotrif

How Do We Make EGFR Inhibitors Work Better for Patients

Play Episode Listen Later Jun 9, 2014 3:15

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.

cancer institute patients treatments geoffrey lung combination oxnard inhibitors work better dana farber cancer institute egfr dana farber gracecast cancergrace tarceva iressa afatinib gefitinib gilotrif

How Do We Make EGFR Inhibitors Work Better for Patients